Quantum BioPharma announces through its subsidiary, FSD Pharma Australia Pty Ltd., that it has received approval by the human ethics review committee, HREC, in Australia for its trial entitled “A Randomized, Double-Blind Placebo Controlled Parallel Group Decentralized Trial to Assess the Safety and Efficacy of FSD202 in Participants with Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome.” The randomized, double-blind, placebo controlled parallel group decentralized trial will enroll 60 patients with idiopathic Mast Cell Activation Syndrome .
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Partners with BitGo for Crypto Asset Security
- Quantum BioPharma partners with BitGo to store crypto currency assets
- Quantum BioPharma Advances MS Treatment with New IND Agreement
- Quantum signs agreement with a global pharmaceutical research organization
- Quantum BioPharma Expands Cryptocurrency Holdings with $1 Million Investment